193 related articles for article (PubMed ID: 19864909)
61. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.
Haldenwanger A; Eling P; Kastrup A; Hildebrandt H
J Alzheimers Dis; 2010; 22(3):971-80. PubMed ID: 20858947
[TBL] [Abstract][Full Text] [Related]
62. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations.
Wallin A; Göthlin M; Gustavsson M; Zetterberg H; Eckerström C; Blennow K; Edman A; Lind K; Nordlund A; Rolstad S
Dement Geriatr Cogn Disord; 2011; 32(3):193-7. PubMed ID: 22057225
[TBL] [Abstract][Full Text] [Related]
63. False recognition correlates with amyloid-beta (1-42) but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive impairment.
Hildebrandt H; Haldenwanger A; Eling P
J Alzheimers Dis; 2009; 16(1):157-65. PubMed ID: 19158431
[TBL] [Abstract][Full Text] [Related]
64. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
Brys M; Pirraglia E; Rich K; Rolstad S; Mosconi L; Switalski R; Glodzik-Sobanska L; De Santi S; Zinkowski R; Mehta P; Pratico D; Saint Louis LA; Wallin A; Blennow K; de Leon MJ
Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968
[TBL] [Abstract][Full Text] [Related]
65. [CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease].
Kaiser E; Schönknecht P; Hunt A; Thomann PA; Pantel J; Schröder J
Z Gerontol Geriatr; 2008 Dec; 41(6):497-501. PubMed ID: 18327693
[TBL] [Abstract][Full Text] [Related]
66. Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer's disease.
Kaiser E; Schoenknecht P; Kassner S; Hildebrandt W; Kinscherf R; Schroeder J
Neurodegener Dis; 2010; 7(4):251-9. PubMed ID: 20551690
[TBL] [Abstract][Full Text] [Related]
67. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia.
Olsson B; Hertze J; Ohlsson M; Nägga K; Höglund K; Basun H; Annas P; Lannfelt L; Andreasen N; Minthon L; Zetterberg H; Blennow K; Hansson O
J Alzheimers Dis; 2013; 34(3):673-9. PubMed ID: 23254629
[TBL] [Abstract][Full Text] [Related]
68. Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 22(4):1223-30. PubMed ID: 20930303
[TBL] [Abstract][Full Text] [Related]
69. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.
Sjögren M; Blomberg M; Jonsson M; Wahlund LO; Edman A; Lind K; Rosengren L; Blennow K; Wallin A
J Neurosci Res; 2001 Nov; 66(3):510-6. PubMed ID: 11746370
[TBL] [Abstract][Full Text] [Related]
70. Characteristic Biomarker and Cognitive Profile in Incipient Mixed Dementia.
Eckerström C; Eckerström M; Göthlin M; Molinder A; Jonsson M; Kettunen P; Svensson J; Rolstad S; Wallin A
J Alzheimers Dis; 2020; 73(2):597-607. PubMed ID: 31815692
[TBL] [Abstract][Full Text] [Related]
71. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways.
Maruyama M; Matsui T; Tanji H; Nemoto M; Tomita N; Ootsuki M; Arai H; Sasaki H
Arch Neurol; 2004 May; 61(5):716-20. PubMed ID: 15148149
[TBL] [Abstract][Full Text] [Related]
72. Cingulum fiber diffusivity and CSF T-tau in patients with subjective and mild cognitive impairment.
Stenset V; Bjørnerud A; Fjell AM; Walhovd KB; Hofoss D; Due-Tønnessen P; Gjerstad L; Fladby T
Neurobiol Aging; 2011 Apr; 32(4):581-9. PubMed ID: 19428143
[TBL] [Abstract][Full Text] [Related]
73. High education may offer protection against tauopathy in patients with mild cognitive impairment.
Rolstad S; Nordlund A; Eckerström C; Gustavsson MH; Blennow K; Olesen PJ; Zetterberg H; Wallin A
J Alzheimers Dis; 2010; 21(1):221-8. PubMed ID: 20413900
[TBL] [Abstract][Full Text] [Related]
74. High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease.
Degerman Gunnarsson M; Lannfelt L; Ingelsson M; Basun H; Kilander L
Dement Geriatr Cogn Disord; 2014; 37(3-4):196-206. PubMed ID: 24157938
[TBL] [Abstract][Full Text] [Related]
75. Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis: report of 2 cases.
Frisoni GB; Galluzzi S; Signorini M; Garibotto V; Paghera B; Binetti G; Canu E; Geroldi C; Perani D
Alzheimer Dis Assoc Disord; 2010; 24(1):108-14. PubMed ID: 19568153
[TBL] [Abstract][Full Text] [Related]
76. Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?
Mitchell AJ; Monge-Argilés JA; Sánchez-Paya J
Pract Neurol; 2010 Aug; 10(4):202-7. PubMed ID: 20647526
[TBL] [Abstract][Full Text] [Related]
77. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.
Mitchell AJ
J Neurol Neurosurg Psychiatry; 2009 Sep; 80(9):966-75. PubMed ID: 19465413
[TBL] [Abstract][Full Text] [Related]
78. CSF biomarker profile and diagnostic value in vascular dementia.
Paraskevas GP; Kapaki E; Papageorgiou SG; Kalfakis N; Andreadou E; Zalonis I; Vassilopoulos D
Eur J Neurol; 2009 Feb; 16(2):205-11. PubMed ID: 19146641
[TBL] [Abstract][Full Text] [Related]
79. Differential Impact of Neurofilament Light Subunit on Cognition and Functional Outcome in Memory Clinic Patients with and without Vascular Burden.
Rolstad S; Berg AI; Eckerström C; Johansson B; Wallin A
J Alzheimers Dis; 2015; 45(3):873-81. PubMed ID: 25633679
[TBL] [Abstract][Full Text] [Related]
80. Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study.
Eckerström C; Olsson E; Klasson N; Berge J; Nordlund A; Bjerke M; Wallin A
J Alzheimers Dis; 2015; 44(1):205-14. PubMed ID: 25201779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
